A Study on Vascular Pain Due to Gemcitabine and According to Clinical Factors.
10.5388/aon.2013.13.4.210
- Author:
So Ryoung SEONG
1
;
Namju LEE
;
Mi Jin LEE
;
Hyun Ah JANG
;
Min Ju SONG
;
Se Jung PARK
;
Jeeyoon KIM
;
Baek Yeol RYOO
Author Information
1. Department of Nursing, Asan Medical Center, Seoul, Korea. chacha813@hanmail.net
- Publication Type:Original Article
- Keywords:
Gemcitabine;
Vascular;
Pain;
Neoplasms
- MeSH:
Body Mass Index;
Body Surface Area;
Drug Therapy;
Drug Therapy, Combination;
Hospitals, General;
Humans;
Medical Records;
Surveys and Questionnaires
- From:Asian Oncology Nursing
2013;13(4):210-221
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: This study was performed to examine vascular pain due to gemcitabine and according to clinical factors. METHODS: The survey was performed with 525 cancer patients visiting chemotherapy infusion room in one general hospital. The data were collected via self-reported questionnaire, researchers observation, and reviewing medical records. Data were analyzed descriptive statistics, t-test, Kruskal-Wallis test, Tukey test using ranks, Jonckheere-Terpstra test, and Spearman correlation analysis were used. RESULTS: The mean scores of the intensity and onset time of vascular pain were 3.06+/-2.16 and 8.13+/-13.13 min, and each other were negative correlaton. Degree of intensity of vascular pain had a significant difference on gender (p=.003), age (p=.004), weight (p=.019), Body mass index (BMI) (p=.005), Body surface area (BSA) (p=.030), infusion time (p<.001), dose (p=.027), dose per minute (p<.001), the number of administered gemcitabine (p=.005), combination chemotherapeutic drug (p=.013) and tumor type (p=.002). Degree of onset time of vascular pain had a significant difference on infusion time (p=.044), combination chemotherapy (p=.001) and injection site (p=.001). CONCLUSION: Patients administrated gemcitabine were experiencing various vascular pain, and vascular pain had a difference on clinical factors. Therefore, oncology nurses should be considered significant clinical factors to implement effective interventions to patients administered gemcitabine.
